Liu, D.; Benzaquen, J.; Morris, L.G.T.; Ilié, M.; Hofman, P.
Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. Cancers 2022, 14, 2816.
https://doi.org/10.3390/cancers14112816
AMA Style
Liu D, Benzaquen J, Morris LGT, Ilié M, Hofman P.
Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. Cancers. 2022; 14(11):2816.
https://doi.org/10.3390/cancers14112816
Chicago/Turabian Style
Liu, Dingxie, Jonathan Benzaquen, Luc G. T. Morris, Marius Ilié, and Paul Hofman.
2022. "Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer" Cancers 14, no. 11: 2816.
https://doi.org/10.3390/cancers14112816
APA Style
Liu, D., Benzaquen, J., Morris, L. G. T., Ilié, M., & Hofman, P.
(2022). Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. Cancers, 14(11), 2816.
https://doi.org/10.3390/cancers14112816